Drug Shortage Notice – Flixotide (flutiscaone) 125mg and 250mg Evohaler

July 8, 2024

Flixotide (fluticasone) 125 micrograms/dose and 250 micrograms/dose Evohaler is out of stock from late June until mid-July 2024.

Alternatives:

Flixotide (fluticasone) Accuhaler 100 microgram, 250 micrograms, and 500 micrograms remain available and can support a full uplift in demand.
Where these are not suitable options, alternative corticosteroid inhalers, including beclomethasone metered dose inhalers, are available.

Advice:

Where patients have insufficient supplies to last until the re-supply date, clinicians should:
Review and discuss treatment options with them taking into account individual clinical requirements e.g., the need for a spacer, to aid selection of an alternative treatment option (see Supporting information).
Consider prescribing a sufficient supply of an appropriate strength Flixotide Accuhaler, a dry powder inhaler (DPI), to last until the resupply date in patients able to use this device.
Where patients are already prescribed a Flixotide 125 micrograms/dose Evohaler and a salmeterol 25micrograms inhaler separately, consider prescribing Seretide 125 Evohaler as this combination inhaler delivers the same doses of these components.
Where patients are already prescribed a Flixotide 250 micrograms/dose Evohaler and a salmeterol inhaler separately, consider prescribing Seretide 250 Evohaler as this combination inhaler delivers the same doses of these components.
If the above options are not appropriate, consider prescribing an alternative inhaled corticosteroid in line with NICE asthma guidelines.

Further information can be found on the Drug Safety Notice here

For further information, contact: